Ou Yamaguchi

15PUBLICATIONS
41CO-AUTHORS
Predictive and prognostic markersCancer geneticsRadiation therapyMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Apr 18, 2025
A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab.

Atsuto Mouri, Hisao Imai, Satoshi Endo

|Apr 16, 2025
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi

|Nov 28, 2023
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).

Ou Yamaguchi, Keita Mori, Saori Takata

|Aug 22, 2023
Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib.

Kyoichi Kaira, Hisao Imai, Atsuto Mouri

|Oct 11, 2022
Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy.

Hiroshi Kagamu, Satoshi Yamasaki, Shigehisa Kitano

|Apr 08, 2022
Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer.

Hisao Imai, Erika Naito, Ou Yamaguchi

Pageof 3

Frequent Collaborators

11 joint publications

Kyoichi Kaira

8 joint publications

Hisao Imai

2 joint publications

Hiroyuki Minemura

2 joint publications

Takayuki Kishikawa